Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.

Drieling RL, LaCroix AZ, Beresford SA, Boudreau DM, Kooperberg C, Chlebowski RT, Gass M, Crandall CJ, Womack CR, Heckbert SR.

Menopause. 2016 Nov;23(11):1168-1175.

PMID:
27433859
2.

New strategies for osteoporosis patients previously managed with strontium ranelate.

Vestergaard P.

Ther Adv Musculoskelet Dis. 2014 Dec;6(6):217-25. doi: 10.1177/1759720X14552070. Review.

3.

Fracture prevention in postmenopausal women.

Vestergaard P, Mosekilde L, Langdahl B.

BMJ Clin Evid. 2011 May 3;2011. pii: 1109. Review.

4.

Emerging therapeutic opportunities for skeletal restoration.

Kawai M, Mödder UI, Khosla S, Rosen CJ.

Nat Rev Drug Discov. 2011 Feb;10(2):141-56. doi: 10.1038/nrd3299. Review.

5.
6.

Update on estrogens and the skeleton.

Khosla S.

J Clin Endocrinol Metab. 2010 Aug;95(8):3569-77. doi: 10.1210/jc.2010-0856. Review.

7.

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY.

Osteoporos Int. 2010 Oct;21(10):1657-80. doi: 10.1007/s00198-010-1223-4. Epub 2010 May 18.

9.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel VG.

Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Mar;9(3):388.

10.

Basic and clinical aspects of osteoporosis in inflammatory bowel disease.

Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK.

World J Gastroenterol. 2007 Dec 14;13(46):6156-65. Review.

Supplemental Content

Support Center